On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Hubei Biocause Heilen Phamaceutical Co., Ltd.

29 YRS

Hubei, China

CNY 180 Million

139860 m²

500-1000 people

Main Products: Torasemide / Ibuprofen / Dexibuprofen / Ibuprofen Lysinate / Granisetron Hydrochloride / Tropisetron Hydrochloride / Dolasetron Mesylate / Fludarabine Phosphate / Abiraterone / Azacytidine / Clofarabine / Atropine Sulfate / Hyoscyamine Sulfate / Milrinone / Flumazenil / Cladribine / Homatropine Methyl Bromide / Oxaprozin / Balsalazide Sodium

Hubei, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

Abiraterone / CAS 154229-19-3

OVERVIEW

Packaging

25 KG/Fibre Drum

Lead Time

14-30 days

REQUEST A QUOTATION

Submit

Get Free Samples

Less than 1KG required

DESCRIPTION

Abiraterone

Name in English: abiraterone

CAS number: 154229-19-3

Molecular formula: C24H31NO

MW: 349.52

EINECS number: 810-941-6

Use: abiraterone, a prostate cancer therapeutic that inhibits androgen production in any part of the body, not only reduces prostate-specific antigen (PSA) levels, which represent tumor activity, but also helps shrink tumors, and at the same time applies to patients with tumors that have undergone chemotherapy in the past, has shown therapeutic promise.

Typical Properties

Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro. Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.

CAS No.

154229-19-3

Formula

C24H31NO

Molecular Mass

349.50900

Exact Mass

349.24100

PSA

33.12000

Logp

5.39860

IUPAC

(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol

SMILES

C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O

Matter Classification

organic

GET SAMPLE